Variability in platelet responsiveness to clopidogrel among 544 individuals
Victor L. Serebruany, MD, PhD*,*,
Steven R. Steinhubl, MD, FACC ,
Peter B. Berger, MD, FACC ,
Alex I. Malinin, MD*,
Deepak L. Bhatt, MD, FACC and
Eric J. Topol, MD, FACC
* HeartDrug Research Laboratories, Towson, Maryland
University of Kentucky, Lexington, Kentucky
Duke Clinical Research Institute, Durham, North Carolina
Cleveland Clinic, Cleveland, Ohio
View larger version (45K):
[in a new window]
|
Figure 1 Distribution of changes in 5 µmol of adenosine diphosphate (ADP)-induced platelet aggregation in 544 patients after receiving clopidogrel therapy. Negative changes in aggregation values represent aggregation values after the administration of clopidogrel that were higher than the baseline readings.
|
|
View larger version (38K):
[in a new window]
|
Figure 2 Distribution of 5 µmol of adenosine diphosphate (ADP)-induced residual platelet aggregation in 544 patients after receiving clopidogrel therapy.
|
|
View larger version (24K):
[in a new window]
|
Figure 3 Correlation between inhibition of platelet activation as determined by the change in platelet/endothelial cell adhesion molecule-1 (PECAM-1) expression and the change in 5 µmol of adenosine diphosphate (ADP)-induced platelet aggregation after treatment with clopidogrel. Negative values resulted from the higher readings after treatment when compared with the baseline measures.
|
|
View larger version (31K):
[in a new window]
|
Figure 4 Platelet inhibition over the course of time for multiple time point assessments (>2) after loading with 300 mg and maintenance dose of 75 mg of clopidogrel.
|
|
|
